| Primary |
| Myasthenia Gravis |
52.3% |
| Product Used For Unknown Indication |
8.1% |
| Drug Use For Unknown Indication |
7.2% |
| Myasthenic Syndrome |
6.3% |
| Neuromyelitis Optica |
5.4% |
| Hypertension |
4.5% |
| Muscular Weakness |
2.7% |
| Myelitis |
1.8% |
| Spinal Muscular Atrophy |
1.8% |
| Asthenia |
0.9% |
| Atrial Fibrillation |
0.9% |
| Cardiac Pacemaker Insertion |
0.9% |
| Constipation |
0.9% |
| Depression |
0.9% |
| Encephalitis Periaxialis Diffusa |
0.9% |
| Herpes Zoster |
0.9% |
| Lung Infection |
0.9% |
| Myasthenia |
0.9% |
| Ocular Hypertension |
0.9% |
| Orthostatic Hypotension |
0.9% |
|
| Renal Failure |
8.7% |
| Drug Exposure During Pregnancy |
6.5% |
| Product Quality Issue |
6.5% |
| Salivary Hypersecretion |
6.5% |
| Therapeutic Response Decreased |
6.5% |
| Cerebrovascular Accident |
4.3% |
| Dysphagia |
4.3% |
| Ileus |
4.3% |
| Malaise |
4.3% |
| Medication Error |
4.3% |
| Pharmaceutical Product Complaint |
4.3% |
| Product Substitution Issue |
4.3% |
| Psychotic Disorder |
4.3% |
| Therapy Non-responder |
4.3% |
| Throat Irritation |
4.3% |
| Toxic Epidermal Necrolysis |
4.3% |
| Urticaria |
4.3% |
| Uterine Hypertonus |
4.3% |
| Vision Blurred |
4.3% |
| Vomiting |
4.3% |
|
| Secondary |
| Myasthenia Gravis |
27.6% |
| Drug Use For Unknown Indication |
19.9% |
| Product Used For Unknown Indication |
19.9% |
| Muscular Weakness |
3.9% |
| Hepatitis C |
3.3% |
| Ocular Myasthenia |
3.3% |
| Psychotic Disorder |
2.8% |
| Arthralgia |
2.2% |
| Drug Exposure During Pregnancy |
2.2% |
| Hypertension |
2.2% |
| Acne |
1.7% |
| Gastrointestinal Disorder |
1.7% |
| Ill-defined Disorder |
1.7% |
| Antiplatelet Therapy |
1.1% |
| Benign Prostatic Hyperplasia |
1.1% |
| Blood Pressure |
1.1% |
| Bronchitis |
1.1% |
| Diabetes |
1.1% |
| Fungal Rhinitis |
1.1% |
| Influenza |
1.1% |
|
| Toxic Epidermal Necrolysis |
15.0% |
| Toxic Skin Eruption |
12.5% |
| Drug Interaction |
7.5% |
| Drug Exposure During Pregnancy |
5.0% |
| Gastrointestinal Disorder |
5.0% |
| Oliguria |
5.0% |
| Palpitations |
5.0% |
| Rash |
5.0% |
| Retroperitoneal Fibrosis |
5.0% |
| Subileus |
5.0% |
| Supraventricular Extrasystoles |
5.0% |
| Vision Blurred |
5.0% |
| Agranulocytosis |
2.5% |
| Cardio-respiratory Arrest |
2.5% |
| Circumstance Or Information Capable Of Leading To Medication Error |
2.5% |
| Death |
2.5% |
| Diarrhoea |
2.5% |
| Drug Hypersensitivity |
2.5% |
| Endocarditis Enterococcal |
2.5% |
| Fatigue |
2.5% |
|
| Concomitant |
| Myasthenia Gravis |
24.2% |
| Product Used For Unknown Indication |
17.7% |
| Drug Use For Unknown Indication |
13.4% |
| Osteoporosis |
4.4% |
| Hypertension |
4.3% |
| Pain |
3.6% |
| Gastrooesophageal Reflux Disease |
3.5% |
| Diabetes Mellitus |
3.5% |
| Hypothyroidism |
3.2% |
| Asthma |
2.7% |
| Depression |
2.6% |
| Prophylaxis |
2.3% |
| Muscular Weakness |
2.1% |
| Muscle Disorder |
1.9% |
| Sinus Disorder |
1.9% |
| Gastric Disorder |
1.8% |
| Rheumatoid Arthritis |
1.8% |
| Atrial Fibrillation |
1.7% |
| Multiple Sclerosis |
1.6% |
| Ulcer |
1.6% |
|
| Myasthenia Gravis |
20.1% |
| Vomiting |
11.3% |
| Weight Decreased |
7.1% |
| Drug Ineffective |
5.0% |
| Weight Increased |
5.0% |
| Wrist Fracture |
5.0% |
| Pulmonary Embolism |
4.6% |
| White Blood Cell Count Increased |
4.6% |
| Tremor |
4.2% |
| Pruritus |
3.8% |
| Pyrexia |
3.8% |
| Respiratory Arrest |
3.8% |
| Hypersensitivity |
3.3% |
| Urinary Tract Infection |
3.3% |
| Aplasia Pure Red Cell |
2.5% |
| Depression |
2.5% |
| Dyspepsia |
2.5% |
| Malaise |
2.5% |
| Respiratory Failure |
2.5% |
| Suicidal Ideation |
2.5% |
|
| Interacting |
| Muscular Weakness |
39.1% |
| Benign Prostatic Hyperplasia |
13.0% |
| Pain |
13.0% |
| Tooth Infection |
13.0% |
| Prophylaxis Against Gastrointestinal Ulcer |
8.7% |
| Myoclonus |
4.3% |
| Prophylaxis |
4.3% |
| Smoking Cessation Therapy |
4.3% |
|
| Drug Interaction |
75.0% |
| Nausea |
25.0% |
|
